Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding

Bluejay Diagnostics, Inc.

SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
Cash & equivalents $5.7M as of April 30, 2025; Q1 2025 net loss $1.9M, FY2024 net loss $7.7M.
April 2025 private placement raised $3.8M gross; company aims to raise at least $30M total through FY2027.
Workforce reduced to 5 employees after CTO departure; cost-saving measures implemented.
Annual meeting June 18, 2025: board to shrink from 6 to 5, reverse stock split proposals to maintain Nasdaq listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.